MX2015012199A - Composiciones de cisplatino liposomal para la terapia contra el cancer. - Google Patents

Composiciones de cisplatino liposomal para la terapia contra el cancer.

Info

Publication number
MX2015012199A
MX2015012199A MX2015012199A MX2015012199A MX2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A MX 2015012199 A MX2015012199 A MX 2015012199A
Authority
MX
Mexico
Prior art keywords
cisplatin
cancer therapy
mol
liposomal cisplatin
lipid
Prior art date
Application number
MX2015012199A
Other languages
English (en)
Inventor
William Mcghee
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of MX2015012199A publication Critical patent/MX2015012199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención proporciona una composición para el tratamiento del cáncer que incluye liposomas zwitteriónicos que consisten esencialmente de: 50-65% en mol de un lípido de fosfatidilcolina, 30-45% en mol de colesterol y 2-8% en mol de un lípido-PEG; y cisplatino. El cisplatino se encapsula en los liposomas en una cantidad tal que la relación del peso total de lípidos con respecto al peso de cisplatino es de aproximadamente 65:1 a aproximadamente 95:1. También se dan a conocer métodos para la preparación de cisplatino liposomal y el tratamiento del cáncer.
MX2015012199A 2013-03-13 2014-03-13 Composiciones de cisplatino liposomal para la terapia contra el cancer. MX2015012199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780272P 2013-03-13 2013-03-13
PCT/US2014/026341 WO2014160337A1 (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Publications (1)

Publication Number Publication Date
MX2015012199A true MX2015012199A (es) 2015-11-30

Family

ID=50439522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012199A MX2015012199A (es) 2013-03-13 2014-03-13 Composiciones de cisplatino liposomal para la terapia contra el cancer.

Country Status (8)

Country Link
US (2) US10039716B2 (es)
EP (1) EP2968142A1 (es)
JP (1) JP6077710B2 (es)
CN (1) CN105209017A (es)
BR (1) BR112015022415A2 (es)
CA (1) CA2903254C (es)
MX (1) MX2015012199A (es)
WO (1) WO2014160337A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5994049B2 (ja) * 2012-10-01 2016-09-21 兵神装備株式会社 吐出システム
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) * 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
EP3352733A1 (en) * 2015-09-21 2018-08-01 Mallinckrodt LLC Improved stability of liposome formulations and uses thereof
CR20180388A (es) * 2016-01-07 2018-09-11 Univ Western Health Sciences Formulaciones para el tratamiento del cáncer de vejiga
US11517539B2 (en) 2016-02-15 2022-12-06 University Of Georgia Research Foundation, Inc. IPA-3-loaded liposomes and methods of use thereof
WO2017200957A1 (en) * 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
CN110381922A (zh) * 2017-01-18 2019-10-25 淡马锡生命科学研究院有限公司 超稳定脂质体增加对有丝分裂细胞的靶向作用
US20190231690A1 (en) * 2017-11-08 2019-08-01 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US20020009488A1 (en) * 1995-05-03 2002-01-24 Polymasc Pharmaceuticals Plc Tissue entrapment
PT929293E (pt) 1996-08-23 2004-03-31 Sequus Pharm Inc Lipossomas contendo um composto de cisplatina
WO1998033481A1 (en) 1997-02-05 1998-08-06 Pharmacia & Upjohn Company Lipid complexes and liposomes of highly insoluble platinum complexes
AU3467001A (en) * 2000-01-28 2001-08-07 Alza Corp Liposomes containing an entrapped compound in supersaturated solution
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
ATE373466T1 (de) * 2001-11-13 2007-10-15 Celator Pharmaceuticals Inc Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
EP2090305A4 (en) 2006-12-08 2012-12-26 Katayama Chemical Ind Co Ltd LIPOSOME ENCAPSULATING HIGH-CONCENTRATION <O> AMINE </ O> COMPLEX, AND PROCESS FOR PRODUCING THE SAME

Also Published As

Publication number Publication date
WO2014160337A1 (en) 2014-10-02
JP2016513651A (ja) 2016-05-16
EP2968142A1 (en) 2016-01-20
CA2903254A1 (en) 2014-10-02
CN105209017A (zh) 2015-12-30
US10039716B2 (en) 2018-08-07
JP6077710B2 (ja) 2017-02-08
BR112015022415A2 (pt) 2017-07-18
US20140271821A1 (en) 2014-09-18
US20180318219A1 (en) 2018-11-08
CA2903254C (en) 2019-04-09
US10383823B2 (en) 2019-08-20

Similar Documents

Publication Publication Date Title
MX2015012199A (es) Composiciones de cisplatino liposomal para la terapia contra el cancer.
MX2015012200A (es) Composiciones de oxaliplatino en liposomas para la terapia contra el cancer.
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
NZ732777A (en) Ionizable cationic lipid for rna delivery
MX360391B (es) Composiciones liposomales combinadas para terapia contra el cancer.
SG10201906075VA (en) Methods of treating cancer
MX2019003334A (es) Composiciones liposomicas de inhibidores de proteasoma basadas en epoxicetona.
MX2021006723A (es) Formulacion para anticuerpo anti-a4b7.
IN2014DN05866A (es)
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX337605B (es) Derivados de fumarato de acido graso y sus usos.
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
IN2014MN00948A (es)
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
WO2008070463A3 (en) Endoxifen methods and compositions
MX352454B (es) Productos para el cuidado oral que comprenden cloruro tetrabasico de zinc y trimetilglicina.
MX360315B (es) Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.
IN2014DN09437A (es)
MX368876B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
GB201114230D0 (en) Addition copolymers and their use
MX2012007682A (es) Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
WO2012117385A3 (en) Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it